Youth may increase vulnerability to a carcinogen found in contaminated water and some drugs
A new study suggests that the chemical NDMA is much more likely to cause cancerous mutations after exposure early in life.
A new study suggests that the chemical NDMA is much more likely to cause cancerous mutations after exposure early in life.
Long thought to be mainly a structural support, the cell membrane also influences how cells respond to signals and may contribute to the growth of cancer cells.
A backup survival pathway can help tumor cells resist certain lung cancer and other drugs. Combining therapies may offer a solution.
As an aspiring physician-scientist and editor-in-chief of The Tech, MIT senior Alex Tang has found inspiration in the lives of patients and others in his community.
Assistant Professor Matthew Jones is working to decode molecular processes on the genetic, epigenetic, and microenvironment levels to anticipate how and when tumors evolve to resist treatment.
Assistant Professor Alison Ringel will investigate the intersection of immunology and aging biology, aiming to define mechanisms that underlie aging-related decline, thanks to a grant from the foundation.
The new system could be used at home or in doctors’ offices to scan people who are at high risk for breast cancer.
Researchers uncover a hidden mechanism that allows cancer to develop aggressive mutations.
Professor, mentor, and leader at MIT for more than 50 years shaped fundamental understandings of cell adhesion, the extracellular matrix, and molecular mechanisms of metastasis.
Nanoparticles coated with molecular sensors could be used to develop at-home tests for many types of cancer.
New research suggests liver cells exposed to too much fat revert to an immature state that is more susceptible to cancer-causing mutations.
Using new molecules that block an immune checkpoint, researchers showed they could stimulate a strong anti-tumor immune response.
A study profiling antigens presented on immune and tumor cells in co-culture points to new strategies for attacking a treatment-resistant and deadly brain cancer.
Therapeutic antibodies packaged into microparticles could be injected with a standard syringe, avoiding the need for lengthy and often uncomfortable infusions.
Using a versatile problem-solving framework, researchers show how early relapse in lymphoma patients influences their chance for survival.